1. The experimental development of bioreductive drugs and their role in cancer therapy

   • P. Workman
   • I. J. Stratford

   OriginalPaper Pages: 73 - 82

2. DT-diaphorase in activation and detoxification of quinones

   • David Ross
   • David Siegel
   • Neil W. Gibson

   OriginalPaper Pages: 83 - 101

3. NAD(P)H:Quinone oxidoreductase₁ (DT-diaphorase) expression in normal and tumor tissues

   • Martin Belinsky
   • Anil K. Jaiswal

   OriginalPaper Pages: 103 - 117

4. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent

   • Laurence H. Patterson

   OriginalPaper Pages: 119 - 134

5. Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs)

   • William A. Denny
   • William R. Wilson

   OriginalPaper Pages: 135 - 151

6. Cellular approaches to bioreductive drug mechanisms

   • A. Michael Rauth
   • Raymond S. Marshall
   • Bonnie L. Kuehl

   OriginalPaper Pages: 153 - 164

7. Cellular pharmacology of quinone bioreductive alkylating agents

   • Sara Rockwell
   • Alan C. Sartorelli
   • Katherine A. Kennedy

   OriginalPaper Pages: 165 - 176

8. Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference toin vivo methods of evaluation

   • Jane C. M. Bremner

   OriginalPaper Pages: 177 - 193

9. The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT)

   • Richard J. Knox
   • Frank Friedlos
   • Marion P. Boland

   OriginalPaper Pages: 195 - 212